Patisiran Can Preserve Functional Capacity in ATTR Amyloidosis

THURSDAY, Oct. 26, 2023-- For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according to a study published...